This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Dynavax Technologies (DVAX) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Dynavax Technologies (DVAX) delivered earnings and revenue surprises of +16.67% and +8.99%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Does Immatics (IMTX) Have the Potential to Rally 174.54% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Immatics (IMTX) points to a 174.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
ImmunityBio (IBRX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
ImmunityBio (IBRX) delivered earnings and revenue surprises of -25% and 5.25%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Cardiff Oncology (CRDF) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Cardiff Oncology (CRDF) delivered earnings and revenue surprises of -5.26% and 33.94%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Day One Biopharmaceuticals, Inc. (DAWN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Day One Biopharmaceuticals (DAWN) delivered earnings and revenue surprises of 23.91% and 4.90%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Eton Pharmaceuticals, Inc. (ETON) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Eton Pharmaceuticals (ETON) delivered earnings and revenue surprises of 0% and 9.05%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Twist Bioscience (TWST) Moves 6.6% Higher: Will This Strength Last?
by Zacks Equity Research
Twist Bioscience (TWST) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Kymera Therapeutics (KYMR) delivered earnings and revenue surprises of -15.79% and 43.50%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Travere (TVTX) Moves 12.6% Higher: Will This Strength Last?
by Zacks Equity Research
Travere (TVTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
New Strong Buy Stocks for February 12th
by Zacks Equity Research
BOH, AUB, BHRB, IMTX and RH have been added to the Zacks Rank #1 (Strong Buy) List on February 12, 2025.
Down -16.85% in 4 Weeks, Here's Why Immatics (IMTX) Looks Ripe for a Turnaround
by Zacks Equity Research
Immatics (IMTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
New Strong Buy Stocks for January 9th
by Zacks Equity Research
AFRM, ZNTL, IMTX, MRCY and DRRX have been added to the Zacks Rank #1 (Strong Buy) List on January 9, 2024.
Immatics (IMTX) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Immatics (IMTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
What Makes Immatics (IMTX) a New Buy Stock
by Zacks Equity Research
Immatics (IMTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Immatics (IMTX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Immatics (IMTX) delivered earnings and revenue surprises of 55.56% and 216.62%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Guardant Health (GH) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Guardant Health (GH) delivered earnings and revenue surprises of 18.18% and 12.72%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Avidity Biosciences, Inc. (RNA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Avidity Biosciences (RNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Immatics (IMTX) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Immatics (IMTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AstraZeneca (AZN) Imfinzi Combo Gets EU Nod for Uterine Cancer
by Zacks Equity Research
AstraZeneca's (AZN) Imfinzi plus Lynparza for treating certain patients with primary advanced or recurrent endometrial cancer is approved in the EU based on data from the phase III DUO-E study.
Syros (SYRS) Falls 62% on Phase II Leukemia Study Termination
by Zacks Equity Research
Syros (SYRS) plummets 62% after the decision to discontinue the leukemia study of its investigational candidate, tamibarotene, due to a low likelihood of success per a planned futility analysis.
Here's Why You Should Invest in BioMarin (BMRN) Stock Now
by Zacks Equity Research
Here, we are discussing some reasons why investing in BioMarin (BMRN) stock now may turn out to be a prudent move.
Immatics (IMTX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Immatics (IMTX) delivered earnings and revenue surprises of 48.57% and 63.40%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Gossamer Bio (GOSS) Q2 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Gossamer Bio (GOSS) delivered earnings and revenue surprises of -4.35% and 40.10%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Pacira (PCRX) Plummets as US Court Deems Exparel Patent Invalid
by Zacks Equity Research
Pacira (PCRX) falls 48% as the District Court of New Jersey rules that the company's '495 patent for its lead drug, Exparel, is not valid.
Insmed (INSM) Lags on Q2 Earnings, Tops Sales, Reiterates View
by Zacks Equity Research
Insmed (INSM) posts mixed second-quarter results. It reaches alignment with the FDA on the primary endpoint of a late-stage study that seeks to expand the label of Arikayce.